An Unusual Case of Ipilimumab/Nivolumab Induced Fulminant Diabetic Ketoacidosis (DKA) in a Non Diabetic Patient - a Case Report

Authors

Randa Abdelmasih, HCA HealthcareFollow
Ramy Abdelmaseih, HCA HealthcareFollow
Jay D. Patel, HCA HealthcareFollow
Elio P. Monsour, HCA HealthcareFollow
Khalid Abusaada, HCA HealthcareFollow

Division

North Florida

Hospital

Ocala Regional Medical Center

Document Type

Abstract

Publication Date

5-8-2020

Keywords

immune checkpoint inhibitors, drug-related side effects and adverse reactions

Disciplines

Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism

Publisher or Conference

Journal of the Endocrine Society

Recommended Citation

Abdelmasih R, Abdelmaseih R, Patel J, et al. SAT-LB112 An Unusual Case of Ipilimumab/Nivolumab Induced Fulminant Diabetic Ketoacidosis (DKA) in a Non Diabetic Patient - a Case Report. J Endocr Soc. 2020 May;4(Suppl_1):SAT-LB112. https://doi.org/10.1210/jendso/bvaa046.1993